Search results for "Lymphoproliferative disease"

showing 5 items of 5 documents

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

2016

We report the outcome of 30 consecutive patients with Hodgkin disease (HD) who underwent single-unit UCBT. Most (90%) patients had failed previous autologous hematopoietic stem cell transplantation. The conditioning regimens were based on combinations of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin. The cumulative incidence (CI) of myeloid engraftment was 90% [95% confidence interval (C.I.), 74-98%] with a median of 18 d (range, 10-48). CI of acute graft-versus-host disease (GvHD) grades II-IV was 30% (95% C.I., 17-44%), while the incidence of chronic GVHD was 42% (95% C.I., 23-77%). The non-relapse mortality (NRM) at 100 d and 4 yr was 30% (95% C.I., 13-4…

MaleHerpesvirus 4 HumanTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceHodgkin's lymphomaIncidence (epidemiology)Graft Survivalumbilical cord blood transplantationHematologyGeneral MedicineMiddle AgedHodgkin DiseaseFludarabine030220 oncology & carcinogenesisAcute DiseaseFemaleCord Blood Stem Cell TransplantationVidarabinemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideThioTEPA03 medical and health sciencesInternal medicinemedicineHumansInfectious MononucleosisBusulfanCyclophosphamideAntilymphocyte Serumbusiness.industryMyeloablative AgonistsHodgkin's lymphomamedicine.diseaseSurvival AnalysisSurgeryEBV post-transplant lymphoproliferative diseaseChronic DiseaseEBV post-transplant lymphoproliferative disease; Hodgkin's disease; Hodgkin's lymphoma; umbilical cord blood transplantationHodgkin's diseasebusinessSettore MED/15 - Malattie del SangueThiotepaBusulfan030215 immunologyEuropean Journal of Haematology
researchProduct

Post-transplant lymphoproliferative disorder in adult renal transplant recipients: case series and review of literature

2021

Post-transplant lymphoproliferative disorder (PTLD) is serious life-threating complication of transplantation. The clinical picture differs from lymphomas observed in the general population, with different manifestation, histopathology, higher aggressiveness with involvement of sites beyond the primary lymph node, and poorer outcome. The objective of the study was to present nine cases of PTLD observed in our centre among the kidney transplant recipient population and discuss the results with up-to-date literature. We performed a retrospective single-centre assessment of PTLD incidence in the cohorts of kidney transplant recipients followed by our centre. We found nine cases of PTLD, five m…

Pediatricsmedicine.medical_specialtyImmunologyPopulationkidney transplantationCase ReportlymphomaPost-transplant lymphoproliferative disorderhemic and lymphatic diseasesImmunology and AllergyMedicineeducationKidney transplantationeducation.field_of_studybusiness.industryIncidence (epidemiology)Rmedicine.diseaseLymphomaTransplantationsurgical procedures operativekidney transplantation.post-transplant lymphoproliferative diseaseMedicinebusinessComplicationRare diseaseCentral European Journal of Immunology
researchProduct

Palatal atypical histiocytic granuloma

2009

In this report, we examine a clinical entity called atypical histiocytic granuloma (AHG), which is characterized by ulceroproliferative lesions that clinically simulate a squamous cell carcinoma or specific granulomatous lesions. AHG histologically shows a histiocytic proliferation and is characterized by specific mitotic activity, which has the potential to be confused with malignant processes of a lymphoid origin. There are few cases reported in the literature, and an adequateknowledge of the process is required in order to avoid a misdiagnosis, especially as regards malignant processes. To our knowledge, a case of this type of lesion in the palate has not yet been described. We present a…

Atypical histiocytic granulomaPseudolymphomaTraumatic granulomaLymphoproliferative diseasesUNESCO:CIENCIAS MÉDICAS
researchProduct

Adherence to immunomodulatory drugs in patients with multiple myeloma

2018

Background Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. Methods All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomi…

MaleQuestionnairesCancer Treatment030204 cardiovascular system & hematologyPharmacistsPlasma Cell DisordersHematologic Cancers and Related DisordersMathematical and Statistical Techniques0302 clinical medicineSurveys and QuestionnairesMedicine and Health SciencesMedical PersonnelProspective StudiesProspective cohort studyMultiple myelomaMultidisciplinaryQStatisticsRHematologyMyelomasProfessionsOncologyResearch Design030220 oncology & carcinogenesisPhysical SciencesMedicineRegression AnalysisFemaleMultiple MyelomaResearch Articlemedicine.drugmedicine.medical_specialtyDrug AdherenceClinical Research DesignScienceLinear Regression AnalysisResearch and Analysis MethodsMedication Adherence03 medical and health sciencesCronbach's alphaInternal medicinemedicineHumansImmunologic FactorsIn patientMyelomas and Lymphoproliferative DiseasesStatistical MethodsAdverse effectAgedLenalidomidePharmacologySurvey Researchbusiness.industryCancers and NeoplasmsPomalidomidemedicine.diseaseThalidomidePeople and PlacesPopulation GroupingsAdverse EventsbusinessMathematicsPLOS ONE
researchProduct

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review

2021

Patients with postransplant lymphoproliferative disease (PTLD) who are refractory to rituximab-based regimens have extremely poor prognosis. Data is lacking in the setting of solid organ transplantation (SOT)-related PTLD treated with chimeric antigen receptor T-cell (CAR-T) therapy. Moreover, limited information is available on the influence of concomitant immunosuppressive drugs on CAR-T function. Here, we describe the clinical outcome in one PTLD patient and propose a strategy for tailoring immunosuppressive treatment and organ monitoring in patients with kidney allografts after CAR-T infusion. This report also reviews the limited published data in the setting of SOT-related PTLD treated…

Oncologymedicine.medical_specialtymedicine.medical_treatmentImmunotherapy AdoptiveGeneral Biochemistry Genetics and Molecular BiologyRefractoryhemic and lymphatic diseasesInternal medicinemedicineHumansKidneyReceptors Chimeric Antigenbusiness.industryImmunosuppressionOrgan TransplantationGeneral MedicineLymphoproliferative DisordersTransplant RecipientsChimeric antigen receptorDiscontinuationsurgical procedures operativemedicine.anatomical_structureConcomitantRituximabLymphoproliferative diseasebusinessmedicine.drugCurrent Research in Translational Medicine
researchProduct